In its second antibody-drug conjugate licensing agreement this year, Ipsen has secured exclusive rights to Foreseen ...

The FDA’s Complete Response Letter turned down Novo Nordisk’s Biologics License Application for its once-weekly basal insulin ...

A recent legal decision could signal the ultimate demise of the FTC’s final rule banning most noncompete clauses. A biotech ...

Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.

Interius BioTherapeutics has received approval to begin a Phase I trial in Australia of an investigational in vivo CAR-T ...

Preliminary data from a late-stage trial of Alnylam’s RNAi therapy for ATTR amyloidosis with cardiomyopathy appear strong, ...

Kazia Therapeutics on Wednesday unveiled additional data from the Phase II/III GBM-AGILE study, picking out secondary ...

Eli Lilly on Monday announced a $3.2 billion all-cash deal to purchase Morphic and its pipeline of oral integrin therapies in ...

Pfizer on Thursday announced that it will move forward with its oral GLP-1 analog danuglipron, which the pharma hopes will ...

The U.S. Federal Trade Commission is gearing up to take the three largest pharmacy benefit managers to court over their ...

The regulator Tuesday added atopic dermatitis to the label of Arcutis Biotherapeutics’ topical PDE4 inhibitor Zoryve for the ...

Artificial intelligence is making it faster to get drug candidates to the clinic, but to gain a competitive advantage, ...